Opportunity Abounds for Celgene (CELG) in Multiple Segments - Cramer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St set for higher open but weekly losses loom
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Celgene (CELG) REVLIMID Approved by China's SFDA
February 11, 2013 7:32 AM ESTCelgene Corp a subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that REVLIMID® (lenalidomide) has been granted full approval, which includes an Import Drug License (IDL) by the China State Food and Drug Administration (SFDA) for use in combination with dexamethasone as a... More
Approval of Celgene's (CELG) Pomalyst Largely Expected by Street (ONXX)
February 8, 2013 6:57 AM ESTCelgene's (Nasdaq: CELG) Pomalyst (pomalidomide) might have some potential after all.
According to a recent Bloomberg survey of five analysts, Pomalyst is likely to win FDA approval for the treatment of multiple myeloma in patients who have failed at... More
